Show simple item record

dc.contributor.authorBrekke, Kurt Richard
dc.contributor.authorDalen, Dag Morten
dc.contributor.authorHolmås, Tor Helge
dc.date.accessioned2013-07-30T08:12:50Z
dc.date.available2013-07-30T08:12:50Z
dc.date.issued2013-03
dc.identifier.issn0804-6824
dc.identifier.urihttp://hdl.handle.net/11250/163404
dc.description.abstractThis paper studies the diffusion of biopharmaceuticals across European countries, focusing on anti-TNF drugs, which are used to treat autoimmune diseases (e.g., rheumatism, psoriasis). We use detailed sales information on the three brands Remi-cade, Enbrel and Humira for nine European countries covering the period from the first launch in 2000 until becoming blockbusters in 2009. Descriptive statistics reveal large variations across countries in per-capita consumption and price levels both overall and at brand level. We explore potential sources for the cross-country consumption differences by estimating several multivariate regression models. Our results show that large parts of the cross-country variation are explained by time-invariant country-specific factors (e.g., disease prevalence, demographics, health care system). We also find that differences in income (GDP per capita) and health spending (share of GDP) explain the cross-country variation in consumption, while relative price differences seem to have limited impact.no_NO
dc.language.isoengno_NO
dc.publisherNorwegian School of Economics. Department of Economicsno_NO
dc.relation.ispartofseriesDiscussion paper;7/2013
dc.subjectdiffusionno_NO
dc.subjectpharmaceuticalsno_NO
dc.subjectcross-country analysisno_NO
dc.titleDiffusion of pharmaceuticals : cross-country evidence of anti-TNF drugsno_NO
dc.typeWorking paperno_NO
dc.subject.nsiVDP::Social science: 200::Economics: 210::Economics: 212no_NO
dc.subject.jelI11
dc.subject.jelL13
dc.subject.jelO33


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record